The Effects of Synaquell on Brain Function

The Effect of Synaquell on Objective Brain Function Measures in Ice Hockey Players

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05041192

Enrollment

Registered

2021-09-10

Start date

2021-09-03

Completion date

2022-04-22

Last updated

2022-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Ice Hockey, Cognitive Function, Cognition, Brain, Supplement, Contact Sport Athletes

Brief summary

The purpose of this study is to investigate the dietary supplement, Synaquell (TM), for effects on brain function.

Detailed description

Ice Hockey players will be administered Synaquell over the course of one season. Each player will be administered Synaquell or a placebo twice, daily. They will be tested during the preseason and the postseason to compare changes in cognitive measures. This is an optimal population, as Synaquell was designed for contact sport athletes and others sustaining frequent head impacts.

Interventions

DIETARY_SUPPLEMENTSynaquell

7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).

DIETARY_SUPPLEMENTPlacebo

7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

18 Years to 21 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 years of age or greater. * Fluent English speakers. * Medically cleared to play ice hockey.

Exclusion criteria

* An allergy to the ingredients of Synaquell or Synaquell+ (Magnesium, beta hydroxybutyrate, Glutathione, N-acetyl-L-cysteine, Riboflavin, Magnesium, Leucine, Isoleucine, Valine, Resveratrol, Curcumin Phytosome, Nicotinamide riboside, Docosahexanoic Acid). * Clinically documented hearing issues. * In-ear hearing aid or cochlear implant. * Implanted pacemaker or defibrillator. * Metal or plastic implants in skull. * Lack of verbal fluency in the English language. * History of seizures. * Allergy to rubbing alcohol or EEG gel. * Unhealthy scalp.

Design outcomes

Primary

Measure	Time frame	Description
Change in brain vital signs	Baseline, Postseason (approximately 6 months)	Obtained by EEG recording of N100, P300, N400 amplitudes and latencies. Increased amplitudes are indicative of larger signals and increased latencies are indicative of slower responses.
Change in blood biomarker	Baseline, Postseason (approximately 6 months)	Neurofilament light chain (NfL) blood serum levels.

Secondary

Measure	Time frame	Description
Change in King-Devick Test (KDT) scores	Baseline, Postseason (approximately 6 months)	A rapid number-naming test that requires individuals to read 3 numbered cards a loud as fast as possible, the resulting time is the KDT score.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026